Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits

Steven David Rhodes, Feng Chun Yang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene, encoding the protein neurofibromin, which functions to negatively regulate Ras-activity. Although neurofibromas are considered the hallmark feature of NF1, up to 70 percent of NF1 patients develop both generalized and focal osseous defects including short stature, kyphoscoliosis, osteopenia/osteoporosis, fractures, and pseudarthrosis (fracture non-union). While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggests that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models demonstrating a requirement for hematopoietic derived NF1 (Nf1) haploinsufficient osteoclasts and their progenitors in the pathogenesis of multiple NF1 skeletal deficits.

Original languageEnglish (US)
Title of host publicationNeurofibromatosis: Diagnosis, Management and Clinical Outcomes
PublisherFuture Medicine Ltd.
Pages15-44
Number of pages30
ISBN (Print)9781634632485, 9781634632294
StatePublished - Oct 1 2014

Fingerprint

Neurofibromatosis 1
Osteoblasts
Osteoclasts
Neurofibromin 1
Haploinsufficiency
Neurofibroma
Inborn Genetic Diseases
Pseudarthrosis
Metabolic Bone Diseases
Tumor Suppressor Genes
Osteoporosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rhodes, S. D., & Yang, F. C. (2014). Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits. In Neurofibromatosis: Diagnosis, Management and Clinical Outcomes (pp. 15-44). Future Medicine Ltd..

Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits. / Rhodes, Steven David; Yang, Feng Chun.

Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd., 2014. p. 15-44.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rhodes, SD & Yang, FC 2014, Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits. in Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd., pp. 15-44.
Rhodes SD, Yang FC. Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits. In Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd. 2014. p. 15-44
Rhodes, Steven David ; Yang, Feng Chun. / Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits. Neurofibromatosis: Diagnosis, Management and Clinical Outcomes. Future Medicine Ltd., 2014. pp. 15-44
@inbook{868252aa34f04407af65d6eb1b1530c1,
title = "Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits",
abstract = "Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene, encoding the protein neurofibromin, which functions to negatively regulate Ras-activity. Although neurofibromas are considered the hallmark feature of NF1, up to 70 percent of NF1 patients develop both generalized and focal osseous defects including short stature, kyphoscoliosis, osteopenia/osteoporosis, fractures, and pseudarthrosis (fracture non-union). While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggests that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models demonstrating a requirement for hematopoietic derived NF1 (Nf1) haploinsufficient osteoclasts and their progenitors in the pathogenesis of multiple NF1 skeletal deficits.",
author = "Rhodes, {Steven David} and Yang, {Feng Chun}",
year = "2014",
month = "10",
day = "1",
language = "English (US)",
isbn = "9781634632485",
pages = "15--44",
booktitle = "Neurofibromatosis: Diagnosis, Management and Clinical Outcomes",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Hematopoietic lineages cooperate with osteoblasts in the initiation and progression of neurofibromatosis type 1 associated skeletal deficits

AU - Rhodes, Steven David

AU - Yang, Feng Chun

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene, encoding the protein neurofibromin, which functions to negatively regulate Ras-activity. Although neurofibromas are considered the hallmark feature of NF1, up to 70 percent of NF1 patients develop both generalized and focal osseous defects including short stature, kyphoscoliosis, osteopenia/osteoporosis, fractures, and pseudarthrosis (fracture non-union). While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggests that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models demonstrating a requirement for hematopoietic derived NF1 (Nf1) haploinsufficient osteoclasts and their progenitors in the pathogenesis of multiple NF1 skeletal deficits.

AB - Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene, encoding the protein neurofibromin, which functions to negatively regulate Ras-activity. Although neurofibromas are considered the hallmark feature of NF1, up to 70 percent of NF1 patients develop both generalized and focal osseous defects including short stature, kyphoscoliosis, osteopenia/osteoporosis, fractures, and pseudarthrosis (fracture non-union). While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggests that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models demonstrating a requirement for hematopoietic derived NF1 (Nf1) haploinsufficient osteoclasts and their progenitors in the pathogenesis of multiple NF1 skeletal deficits.

UR - http://www.scopus.com/inward/record.url?scp=84958012716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958012716&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84958012716

SN - 9781634632485

SN - 9781634632294

SP - 15

EP - 44

BT - Neurofibromatosis: Diagnosis, Management and Clinical Outcomes

PB - Future Medicine Ltd.

ER -